Refine by
Cancer Biomarkers Articles & Analysis: Older
32 news found
Antibody-based therapies have witnessed unprecedented success in treating a wide array of diseases, from cancer to autoimmune disorders. However, the traditional antibody discovery process is labor-intensive, time-consuming, and costly. ...
Poster title: “Quantification of Beta-Hydroxybutyric acid and Tryptophan in plasma as metabolic biomarkers of cancer using the LDTD-MS/MS technique”. The poster attracted interest from many potential companies in the clinical lab space on the use of this novel integrated technology for cancer screening application. ...
The most recent performance data on Cancer Targeted Technology’s (CTT) leading drugs, CTT1057 and CTT1403, in prostate cancer clinical and preclinical studies will be presented at several scientific and business meetings in June and one that took place in April, the company announced in a press release. ...
xCures, Inc. is proud to announce their collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company. mProbe utilizes a proprietary technology platform integrating artificial intelligence and multi-omic diagnostics to transform the diagnosis, prevention, and treatment of complex diseases such as cancer. As the knowledge of cancer and ...
ByxCures
This unique public-private partnership between an innovative NHS organisaiton and a world leading cancer theranostic company is breaking down a significant barrier to biomarker testing helping clinical colleagues more easily personalise care for patients with cancer”. ...
Two powerhouse researchers in prostate cancer will change the way we treat the disease, thanks to funding from legendary volunteer fundraisers, the Bird Dogs and the Alberta Cancer Foundation. ...
THE KIT OFFERS A COMPLETE WORKFLOW SOLUTION TO ENABLE LABORATORIES WITH NGS CAPABILITIES TO SUPPORT ONCOLOGISTS IN FINDING THE MOST EFFECTIVE AND PERSONALIZED TREATMENTS FOR THEIR CANCER PATIENTS. The OncoDEEP Kit integrates both reagents and quality control reporting for sequencing over 600 cancer genes and relevant biomarkers, together with ...
Ariana Pharma and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Ariana Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have the potential to expand personalized cancer ...
Blood-based test holds potential for broad applicability for the management of patients with cancer. Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced the publication of a study in the journal npj Precision Oncology that describes the discovery and validation of miRisk, a first-of-its-kind ...
SYNLAB LABORATORIES TO PERFORM ONCODEEP® BIOMARKER TEST TO HELP DOCTORS DECIDE ON THE MOST EFFECTIVE TREATMENT FOR THEIR CANCER PATIENTS ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, ANNOUNCED TODAY A PARTNERSHIP WITH SYNLAB, EUROPE’S LEADING CLINICAL ...
Joint research of biomarkers on platform technology of GI Innovation, GI-SMART™, and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next-generation immuno-oncology, personalized cancer treatment effects… increasing reliability and efficiency of treatment GI Innovation, an ...
Joint research of biomarkers on platform technology of GI Innovation, GI-SMARTTM and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next generation immuno-oncology, personalized cancer treatment effects… increasing Reliability and efficiency of treatment GI Innovation, a new ...
THE KIT OFFERS A COMPLETE WORKFLOW SOLUTION WHICH ENABLES LABORATORIES WITH NGS CAPABILITIES TO PERFORM COMPREHENSIVE BIOMARKER TESTING, PROVIDE POWERFUL DATA ANALYSIS AND SUPPORT ONCOLOGISTS IN THE MOST EFFECTIVE AND PERSONALIZED TREATMENTS FOR THEIR CANCER PATIENTS. THE ONCODEEP KIT INTEGRATES BOTH REAGENTS AND QUALITY CONTROL STANDARDS FOR THE SEQUENCING OF ...
To be part of the EIC Accelerator is a big boost for the company and the commercialization of Amadix’ firs product, PREVECOL® (previously known as Colofast), a test for the early detection of colorectal cancer in blood combining biomarkers and artificial intelligence tools. ...
ByAmadix
THE TWO BELGIAN COMPANIES WILL WORK TOWARDS A BETTER UNDERSTANDING OF NON-SMALL CELL LUNG CANCER BIOLOGY AND CHARACTERIZATION OF THE TUMORS USING AI TECHNOLOGY Radiomics and OncoDNA are pleased to announce that they have entered into a strategic agreement, combining Radiomics’ next-generation AI-based technology to extract quantitative information embedded in medical ...
MiraDx, in collaboration with the UCLA Jonsson Comprehensive Cancer Center, is conducting a clinical trial to validate a novel prostate cancer biomarker panel designed to help assess patients who were at a greater risk of having long-term toxicity in response to their radiation treatment, to help guide treatment decisions. ...
ByMiraDx
Austin, TX, September 27, 2021 -- Veravas, Inc., an early-stage diagnostics company, has announced the development of its VeraPrep™ Antibody Detection Kit, a new development platform that provides scientists with a state-of-the-art research tool to easily and quickly develop new tests to multiplex detect and measure immunoglobulins against new and emerging pathogens as well as ...
Cancer Targeted Technology (CTT) receives milestone payment for development of diagnostic PET imaging agent for prostate cancer. ...
ESR1 mutations are found in primary breast cancers prior to therapy initiation and are associated to worse relapse-free and overall survival. These results were reported today by a group of researchers from Lund University and Skåne University Hospital in a new studied published in JNCI Cancer Spectrum. The estrogen receptor alpha is one of the most ...
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has finalised its move to purpose-configured facilities at Chesterford Research Park, to accommodate its long-term growth requirements. ...